Literature DB >> 22589540

Tyrosine kinase Btk is required for NK cell activation.

Yan Bao1, Jian Zheng, Chaofeng Han, Jing Jin, Huanxing Han, Yinping Liu, Yu-Lung Lau, Wenwei Tu, Xuetao Cao.   

Abstract

Bruton tyrosine kinase (Btk) is not only critical for B cell development and differentiation but is also involved in the regulation of Toll-like receptor-triggered innate response of macrophages. However, whether Btk is involved in the regulation of natural killer (NK) cell innate function remains unknown. Here, we show that Btk expression is up-regulated during maturation and activation of mouse NK cells. Murine Btk(-/-) NK cells have decreased innate immune responses to the TLR3 ligand, with reduced expressions of IFN-γ, perforin, and granzyme-B and decreased cytotoxic activity. Furthermore, Btk is found to promote TLR3-triggered NK cell activation mainly by activating the NF-κB pathway. Poly(I:C)-induced NK cell-mediated acute hepatitis was observed to be attenuated in Btk(-/-) mice or the mice with in vivo administration of the Btk inhibitor. Correspondingly, liver damage was aggravated in Btk(-/-) mice after the adoptive transfer of Btk(+/+) NK cells, further indicating that Btk-mediated NK cell activation contributes to TLR3-triggered acute liver injury. Importantly, reduced TLR3-triggered activation of human NK cells was observed in Btk-deficient patients with X-linked agammaglobulinemia, as evidenced by the reduced IFN-γ, CD69, and CD107a expression and cytotoxic activity. These results indicate that Btk is required for activation of NK cells, thus providing insight into the physiological significance of Btk in the regulation of immune cell functions and innate inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589540      PMCID: PMC3390651          DOI: 10.1074/jbc.M112.372425

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  Cytotoxic immunological synapses.

Authors:  Michael L Dustin; Eric O Long
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells.

Authors:  Brian Becknell; Tiffany L Hughes; Aharon G Freud; Bradley W Blaser; Jianhua Yu; Rossana Trotta; Hsiaoyin C Mao; Marie L Caligiuri de Jesús; Mohamad Alghothani; Don M Benson; Amy Lehman; David Jarjoura; Danilo Perrotti; Michael D Bates; Michael A Caligiuri
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

3.  Btk regulates multiple stages in the development and survival of B-1 cells.

Authors:  Cristina M Contreras; Kristina E Halcomb; Lindsey Randle; Rochelle M Hinman; Toni Gutierrez; Stephen H Clarke; Anne B Satterthwaite
Journal:  Mol Immunol       Date:  2007-01-04       Impact factor: 4.407

4.  Tyrosine phosphorylation / dephosphorylation balance is involved in thrombin-evoked microtubular reorganisation in human platelets.

Authors:  Aicha Bouaziz; Nidhal Ben Amor; Geoffrey E Woodard; Hanen Zibidi; José J López; Ahgleb Bartegi; Ginés M Salido; Juan A Rosado
Journal:  Thromb Haemost       Date:  2007-08       Impact factor: 5.249

5.  Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-gamma).

Authors:  Rui Sun; Bin Gao
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Involvement of natural killer cells in PolyI:C-induced liver injury.

Authors:  Zhongjun Dong; Haiming Wei; Rui Sun; Zhiqing Hu; Bin Gao; Zhigang Tian
Journal:  J Hepatol       Date:  2004-12       Impact factor: 25.083

Review 7.  Silencing of the mammalian X chromosome.

Authors:  Jennifer C Chow; Ziny Yen; Sonia M Ziesche; Carolyn J Brown
Journal:  Annu Rev Genomics Hum Genet       Date:  2005       Impact factor: 8.929

8.  Opposing roles of NF-kappaB family members in the regulation of NK cell proliferation and production of IFN-gamma.

Authors:  Cristina M Tato; Nicola Mason; David Artis; Sagi Shapira; Jorge C Caamano; Jay H Bream; Hsiou-Chi Liou; Christopher A Hunter
Journal:  Int Immunol       Date:  2006-02-15       Impact factor: 4.823

9.  The beta2 integrin CD11b attenuates polyinosinic:polycytidylic acid-induced hepatitis by negatively regulating natural killer cell functions.

Authors:  Minggang Zhang; Yanmei Han; Chaofeng Han; Sheng Xu; Yan Bao; Zhubo Chen; Yan Gu; Dajing Xia; Xuetao Cao
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

10.  Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity.

Authors:  Tomohiro Kubo; Yuki Uchida; Yuko Watanabe; Masahiro Abe; Akira Nakamura; Masao Ono; Shizuo Akira; Toshiyuki Takai
Journal:  J Exp Med       Date:  2009-08-17       Impact factor: 14.307

View more
  30 in total

1.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  Impaired NK cell antiviral cytokine response against influenza virus in small-for-gestational-age neonates.

Authors:  Jinrong Li; Hong Li; Huawei Mao; Meixing Yu; Fan Yang; Ting Feng; Yingying Fan; Qiao Lu; Chongyang Shen; Zhongwei Yin; Meng Mao; Wenwei Tu
Journal:  Cell Mol Immunol       Date:  2013-07-22       Impact factor: 11.530

Review 3.  Impact of dietary components on NK and Treg cell function for cancer prevention.

Authors:  Young S Kim; Thomas J Sayers; Nancy H Colburn; John A Milner; Howard A Young
Journal:  Mol Carcinog       Date:  2015-04-01       Impact factor: 4.784

4.  Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.

Authors:  Iván Fernández-Vega; Luis M Quirós; Jorge Santos-Juanes; María Pane-Foix; Teresa Marafioti
Journal:  Virchows Arch       Date:  2014-11-30       Impact factor: 4.064

5.  Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Authors:  Fabio Da Roit; Patrick J Engelberts; Ronald P Taylor; Esther C W Breij; Giuseppe Gritti; Alessandro Rambaldi; Martino Introna; Paul W H I Parren; Frank J Beurskens; Josée Golay
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

Review 6.  B-lymphocyte tolerance and effector function in immunity and autoimmunity.

Authors:  Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

7.  Proteomic analysis reveals distinctive protein profiles involved in CD8+ T cell-mediated murine autoimmune cholangitis.

Authors:  Weici Zhang; Ren Zhang; Jun Zhang; Ying Sun; Patrick Sc Leung; Guo-Xiang Yang; Zongwen Shuai; William M Ridgway; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

8.  The tyrosine kinase Btk regulates the macrophage response to Listeria monocytogenes infection.

Authors:  Afitap Derya Köprülü; Renate Kastner; Sebastian Wienerroither; Caroline Lassnig; Eva Maria Putz; Olivia Majer; Benjamin Reutterer; Veronika Sexl; Karl Kuchler; Mathias Müller; Thomas Decker; Wilfried Ellmeier
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

Review 9.  Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.

Authors:  Rossana Maffei; Stefania Fiorcari; Silvia Martinelli; Leonardo Potenza; Mario Luppi; Roberto Marasca
Journal:  J Hematol Oncol       Date:  2015-05-29       Impact factor: 17.388

10.  Role of inositol phospholipid signaling in natural killer cell biology.

Authors:  Matthew Gumbleton; William G Kerr
Journal:  Front Immunol       Date:  2013-03-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.